POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Summary

The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections. The study will enroll patients with moderate to severe AD to receive the 300 mg treatment. BSI-045B wil be firstly given weekly during Week 1 to Week 4, and then every 2 weeks (Q2W) to Week 24.

Timeline

Start

2023-07-31

Primary completion

2024-09-18

Completion

2024-09-18

Drugs

Indications